492,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by MUFG Securities EMEA plc

MUFG Securities EMEA plc bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 492,000 shares of the company’s stock, valued at approximately $10,676,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares in the last quarter. American Century Companies Inc. grew its stake in Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after buying an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp grew its stake in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ROIV. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company. TD Cowen boosted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $29.99 on Monday. Roivant Sciences Ltd. has a 52-week low of $10.59 and a 52-week high of $32.79. The stock has a market capitalization of $21.57 billion, a price-to-earnings ratio of -49.98 and a beta of 1.13. The company has a fifty day moving average of $28.63 and a 200-day moving average of $25.42.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The company had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. During the same quarter in the prior year, the company earned ($0.29) EPS. On average, equities research analysts forecast that Roivant Sciences Ltd. will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, CAO Jennifer Humes sold 13,538 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. This trade represents a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 945,173 shares of company stock worth $27,654,456 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.